LAB vs. TXG, TRNS, EYPT, ALNT, CTKB, AEHR, QSI, QTRX, SENS, and MASS
Should you be buying Standard BioTools stock or one of its competitors? The main competitors of Standard BioTools include 10x Genomics (TXG), Transcat (TRNS), EYEPOINT PHARMACEUTICALS (EYPT), Allient (ALNT), Cytek Biosciences (CTKB), Aehr Test Systems (AEHR), Quantum-Si (QSI), Quanterix (QTRX), Senseonics (SENS), and 908 Devices (MASS). These companies are all part of the "measuring and control equipment" industry.
Standard BioTools vs. Its Competitors
10x Genomics (NASDAQ:TXG) and Standard BioTools (NASDAQ:LAB) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, dividends, risk and institutional ownership.
10x Genomics has a net margin of -25.14% compared to Standard BioTools' net margin of -78.24%. Standard BioTools' return on equity of -22.44% beat 10x Genomics' return on equity.
84.7% of 10x Genomics shares are held by institutional investors. Comparatively, 53.7% of Standard BioTools shares are held by institutional investors. 9.4% of 10x Genomics shares are held by company insiders. Comparatively, 23.2% of Standard BioTools shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
10x Genomics has a beta of 2.03, indicating that its share price is 103% more volatile than the S&P 500. Comparatively, Standard BioTools has a beta of 1.54, indicating that its share price is 54% more volatile than the S&P 500.
In the previous week, 10x Genomics had 11 more articles in the media than Standard BioTools. MarketBeat recorded 11 mentions for 10x Genomics and 0 mentions for Standard BioTools. Standard BioTools' average media sentiment score of 1.89 beat 10x Genomics' score of 0.90 indicating that Standard BioTools is being referred to more favorably in the news media.
10x Genomics presently has a consensus price target of $14.96, indicating a potential upside of 15.00%. Standard BioTools has a consensus price target of $2.50, indicating a potential upside of 82.48%. Given Standard BioTools' stronger consensus rating and higher possible upside, analysts clearly believe Standard BioTools is more favorable than 10x Genomics.
Standard BioTools has lower revenue, but higher earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Standard BioTools, indicating that it is currently the more affordable of the two stocks.
Summary
Standard BioTools beats 10x Genomics on 10 of the 16 factors compared between the two stocks.
Get Standard BioTools News Delivered to You Automatically
Sign up to receive the latest news and ratings for LAB and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding LAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Standard BioTools Competitors List
Related Companies and Tools
This page (NASDAQ:LAB) was last updated on 7/3/2025 by MarketBeat.com Staff
Free LAB Stock Alerts